Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
To assess the association between diabetes mellitus (DM) and the incidence of cancer at different sites.
Data from the baseline and first three follow-up visits of the Atherosclerosis Risk in Communities (ARIC) study, an ongoing cohort study of adults from four American communities, were used in this study. Of 15,792 persons aged 45–64 years old who participated in the baseline visit, the data of 15,118 participants were available for this study. For each cancer site, a conditional stratified Poisson regression model was fitted to estimate the adjusted relative rate and 95% confidence interval (adj. RR, 95% CI) of its incidence in diabetics compared to non-diabetics.
We excluded 850 participants with a history of cancer at baseline and 149 participants who developed cancer during 2 years after enrollment, leaving a total of 14,119 participants of whom 1721 were diabetics. Independent of age, body mass index, alcohol consumption, and physical activity, DM decreased the risk of all cancers combined (adj. RR: 0.77, 95% CI: 0.60, 0.98) and the risk of prostate cancer (adj. RR: 0.51, 95% CI: 0.27, 0.97) and increased the risk of colorectal cancer in non-menopausal women (adj. RR: 12.08, 95% CI: 2.06, 70.94).
In conclusion, DM may be associated with an increased risk of colorectal cancer in non-menopausal women and a decreased risk of prostate cancer and all cancers combined.
Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten
Burden G, Fitzmaurice C, Akinyemiju TF, Al Lami FH, Alam T, Alizadeh-Navaei R, et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2016: a systematic analysis for the global burden of disease study 2016. JAMA Oncol. 2018;4:1553–68. CrossRef
Naghavi M, Abajobir AA, Abbafati C, Abbas KM, Abd-Allah F, Abera SF, et al. Global, regional, and national age-sex specific mortality for 264 causes of death, 1980–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017;390:1151–210. CrossRef
Ogurtsova K, da Rocha Fernandes JD, Huang Y, Linnenkamp U, Guariguata L, Cho NH, et al. IDF diabetes atlas: global estimates for the prevalence of diabetes for 2015 and 2040. Diabetes Res Clin Pract. 2017;128:40–50. CrossRef
Tsilidis KK, Kasimis JC, Lopez DS, Ntzani EE, Ioannidis JP. Type 2 diabetes and cancer: umbrella review of meta-analyses of observational studies. BMJ. 2015;350:g7607. CrossRef
Johnson JA, Bowker SL, Richardson K, Marra CA. Time-varying incidence of cancer after the onset of type 2 diabetes: evidence of potential detection bias. Diabetologia. 2011;54:2263–71. CrossRef
Aric Investigators. The Atherosclerosis Risk in Communities (ARIC) study: design and objects. Am J Epidemiol. 1989;129:687–702. CrossRef
World HealthOrganization. International statistical classification of disease and related health problems, tenth revision (ICD-10). Geneva: World Health Organization; 1992.
Richardson DB, Langholz B. Background stratified Poisson regression analysis of cohort data. Radiat Environ Biophys. 2012;51:15–22. CrossRef
National Cancer Institute (NCI). Risk Factors for Cancer. https://www.cancer.gov/about-cancer/causes-prevention/risk. Accessed 16 Mar 2018.
Li Q, Kuriyama S, Kakizaki M, Yan H, Sone T, Nagai M, et al. History of diabetes mellitus and the risk of prostate cancer: the Ohsaki Cohort Study. Cancer Causes Control. 2010;21:1025–32. CrossRef
Tseng CH. Diabetes and risk of prostate cancer: a study using the National Health Insurance. Diabetes Care. 2011;34:616–21. CrossRef
Lee MY, Lin KD, Hsiao PJ, Shin SJ. The association of diabetes mellitus with liver, colon, lung, and prostate cancer is independent of hypertension, hyperlipidemia, and gout in Taiwanese patients. Metabolism. 2012;61:242–9. CrossRef
Tsilidis KK, Allen NE, Appleby PN, Rohrmann S, Nöthlings U, Arriola L, et al. Diabetes mellitus and risk of prostate cancer in the European prospective investigation into cancer and nutrition. Int J Cancer. 2015;136:372–81. CrossRef
Gudmundsson J, Sulem P, Steinthorsdottir V, Bergthorsson JT, Thorleifsson G, Manolescu A, et al. Two variants on chromosome 17 confer prostate cancer risk, and the one in TCF2 protects against type 2 diabetes. Nat Genet. 2007;39:977–83. CrossRef
Machiela MJ, Lindström S, Allen NE, Haiman CA, Albanes D, Barricarte A, et al. Association of type 2 diabetes susceptibility variants with advanced prostate cancer risk in the breast and prostate cancer cohort consortium. Am J Epidemiol. 2012;176:1121–9. CrossRef
Robinson D, Garmo H, Bill-Axelson A, Mucci L, Holmberg L, Stattin P. Use of 5α-reductase inhibitors for lower urinary tract symptoms and risk of prostate cancer in Swedish men: nationwide, population based case-control study. BMJ. 2013;346:f3406. CrossRef
Ding EL, Song Y, Malik VS, Liu S. Sex differences of endogenous sex hormones and risk of type 2 diabetes: a systematic review and meta-analysis. JAMA. 2006;295:1288–99. CrossRef
Miulescu RD, Dănoiu S, Margină D, Păun S, Poiană C. Dynamics of prostate-specific antigen levels during treatment with testosterone undecanoate in patients with type 2 diabetes mellitus. Rom J Diabetes Nutr Metab Dis. 2012;19:397–403.
Nilsen TL, Vatten LJ. Prospective study of colorectal cancer risk and physical activity, diabetes, blood glucose, and BMI: exploring the hyperinsulinemia hypothesis. Br J Cancer. 2001;84:417–22. CrossRef
de Jong RG, Burden AM, de Kort S, van Herk-Sukel MP, Vissers PA, Janssen PK, et al. Impact of detection bias on the risk of gastrointestinal cancer and its subsites in type 2 diabetes mellitus. Eur J Cancer. 2017;79:61–71. CrossRef
Larsson SC, Orsini N, Wolk A. Diabetes mellitus and risk of colorectal cancer: a meta-analysis. J Natl Cancer Inst. 2005;97:1679–87. CrossRef
Wu L, Yu C, Jiang H, Tang J, Huang HL, Gao J, et al. Diabetes mellitus and the occurrence of colorectal cancer: an updated meta-analysis of cohort studies. Diabetes Technol Ther. 2013;15:419–27. CrossRef
Deng L, Gui Z, Zhao L, Wang J, Shen L. Diabetes mellitus and the incidence of colorectal cancer: an updated systematic review and meta-analysis. Dig Dis Sci. 2012;57:1576–85. CrossRef
Krämer HU, Schöttker B, Raum E, Brenner H. Type 2 diabetes mellitus and colorectal cancer: a meta-analysis on sex-specific differences. Eur J Cancer. 2012;48:1269–82. CrossRef
Luo W, Cao Y, Liao C, Gao F. Diabetes mellitus and the incidence and mortality of colorectal cancer: a meta-analysis of 24 cohort studies. Color Dis. 2012;14:1307–12. CrossRef
Sun L, Yu S. Diabetes mellitus is an independent risk factor for colorectal cancer. Dig Dis Sci. 2012;57:1586–97. CrossRef
González N, Prieto I, del Puerto-Nevado L, Portal-Nuñez S, Ardura JA, Corton M, et al. 2017 update on the relationship between diabetes and colorectal cancer: epidemiology, potential molecular mechanisms, and therapeutic implications. Oncotarget. 2017;8:18456. CrossRef
Will JC, Galuska DA, Vinicor F, Calle EE. Colorectal cancer: another complication of diabetes mellitus? Am J Epidemiol. 1998;147:816–25. CrossRef
Strickler HD, Wylie-Rosett J, Rohan T, Hoover DR, Smoller S, Burk RD, et al. The relation of type 2 diabetes and cancer. Diabetes Technol Ther. 2001;3:263–74. CrossRef
Giovannucci E. Insulin, insulin-like growth factors and colon cancer: a review of the evidence. J Nutr. 2001;131:3109S–20S. CrossRef
Palmqvist R, Stattin P, Rinaldi S, Biessy C, Stenling R, Riboli E, et al. Plasma insulin, IGF-binding proteins-1 and-2 and risk of colorectal cancer: a prospective study in northern Sweden. Int J Cancer. 2003;107:89–93. CrossRef
Sasazuki S, Charvat H, Hara A, Wakai K, Nagata C, Nakamura K, et al. Diabetes mellitus and cancer risk: a pooled analysis of eight cohort studies in Japan. Cancer Sci. 2013;104:1499–507. CrossRef
Schairer C, Gadalla SM, Pfeiffer RM, Moore SC, Engels EA. Diabetes, abnormal glucose, dyslipidemia, hypertension and risk of inflammatory and other breast cancer. Cancer Epidemiol Biomark Prev. 2017;26:862–8. CrossRef
Lipscombe LL, Fischer HD, Austin PC, Fu L, Jaakkimainen RL, Ginsburg O, et al. The association between diabetes and breast cancer stage at diagnosis: a population-based study. Breast Cancer Res Treat. 2015;150:613–20. CrossRef
Hou G, Zhang S, Zhang X, Wang P, Hao X, Zhang J. Clinical, pathological characteristics and prognostic analysis of 1,013 breast cancer patients with diabetes. Breast Cancer Res Treat. 2013;137:807–16. CrossRef
De Bruijn KM, Arends LR, Hansen BE, Leeflang S, Ruiter R, Van Eijck CH. Systematic review and meta-analysis of the association between diabetes mellitus and incidence and mortality in breast and colorectal cancer. Br J Surg. 2013;100:1421–9. CrossRef
Rose DP, Vona-Davis L. The cellular and molecular mechanisms by which insulin influences breast cancer risk and progression. Endocr Relat Cancer. 2012;19:R225–41. CrossRef
Luo J, Beresford S, Chen C, Chlebowski R, Garcia L, Kuller L, et al. Association between diabetes, diabetes treatment and risk of developing endometrial cancer. Br J Cancer. 2014;111:1432–9. CrossRef
Friberg E, Orsini N, Mantzoros CS, Wolk A. Diabetes mellitus and risk of endometrial cancer: a meta-analysis. Diabetologia. 2007;50:1365–74. CrossRef
Bonovas S, Filioussi K, Tsantes A. Diabetes mellitus and risk of prostate cancer: a meta-analysis. Diabetologia. 2004;47:1071–8. CrossRef
- Diabetes mellitus and cancer incidence: the Atherosclerosis Risk in Communities (ARIC) cohort study
Mohammad Ali Mansournia
- Springer International Publishing
Journal of Diabetes & Metabolic Disorders
Elektronische ISSN: 2251-6581
Neu im Fachgebiet Innere Medizin
Meistgelesene Bücher aus der Inneren Medizin
Mail Icon II